News About: Med. Insurance
Civic group calling for rapid screening process of hyperlipidemic medicines
The Korean Pharmacists for Democratic Society said in a statement that the government would have to shorten its screening process period over the economic effectiveness of hyperlipidemic drugs.
The statement said t...
Some multinationals to stage uphill battle in maintaining initial insurance price
Despite their favorable ruling over the trial to confirm the scope of patent rights, some multinational drug manufacturers, such as Pfizer and Sanofi-Aventis, are unlikely to see their reduced insurance prices to the ...
Positive list system faces backlash
The Health Insurance Review & Assessment Service will have to re-evaluate the economic effectiveness of antihyperlipemic agents, as 20 pharmaceutical firms – Pfizer Korea, AstraZeneca Korea and Novartis Korea – asked ...
Launching of new prescription pain treatment to be delayed
Janssen Korea says Jurnista prolonged-release tablets (hydromorphone HCl), a new prescription treatment for severe pain, will not be available on market in September, as its price negotiation with the National Health ...
Korean medicines deemed inexpensive
A survey of 202 medicinal products showed that Korean medicines are reasonable by global standards.
The Korea Pharmaceutical Manufacturers Association reported that 202 out of 1,299 generic products are cheaper tha...
Prices of Janssen’s Prezista, Dacogen to be made public in August
The Ministry of Health, Welfare and Family Affairs says it will announce terms for health insurance allowance for Prezista tablet and Dacogen injection next month due to Janssen Korea’ request to delay the price notic...
ImQuest to file IND of anti-HIV drug
ImQuest Pharmaceuticals Inc. expects to submit an IND in the United States to initiate Phase 1 human clinical trials with IQP·0410, a highly potent member of the pyrimidinedione series in the third quarter of 2008, ac...
National health insurance allowances total 12.9 trillion won in first half
The National Health Insurance Corporation says that health insurance payment in the first half of this year amounted to 12.9 trillion won, up 7.9 percent from the same period of last year.
Medical outlays at pharma...
Low-priced, exit-prevention medicines to be waivered from obligatory small package system in August
The Korea Food and Drug Administration plans to revamp the controversial small package system, to this effect that low-priced drugs of less than 50 won in price tag and/or exit-prevention medicines should be excluded ...
Enbrel’s health insurance coverage extended
Wyeth Korea says that patients with rheumatoid arthritis, who were not responsive to conventional tumor necrosis factor (TNF) inhibitors, have been benefitting from more extended reimbursement period of Enbrel (etaner...
